Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: PRnewswire
Correction on CVR Issuance: Kintara Therapeutics announced a correction regarding the issuance of Contingent Value Rights (CVRs) to stockholders, stating that they will be issued immediately prior to a planned reverse stock split rather than based on an earlier record date.
Merger and Stock Split Details: The proposed merger with TuHURA Biosciences is expected to close on October 18, 2024, following a reverse stock split at a ratio of 1-for-35, with stockholders receiving one CVR per share owned before the split.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
